Diabetes mellitus: A clinical laboratory perspective

Laboratory Medicine

Volumn 37, Issue 5, 2006, Pages 292-297

  Ogedegbe, Henry O ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; BODY FLUID; CARCINOGENESIS; DNA DENATURATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; ONCOGENE K RAS; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVIEW; SENSITIVITY AND SPECIFICITY;

EID: 33646338516     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/X3D971TVRCM0XA6V     Document Type: Review

References (40)

1. Burtis CA, Ashwood ER. Tietz Fundamentale of Clinical Chemistry 5th edition; Philadelphia: W.B. Saunders Company. 2001;421-467.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005;28:S37-S42.
3. Bishop ML, Duben-Engelkirk JL, Fody EP. Clinical Chemistry, Principles, Procedures, Correlation, 2nd edition. Philadelphia; J.B. Lippincott Company, Philadelphia 1992.
4. National Diabetes Data Group; Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes. 1979;28:1039-1057.
5. Sacks DB, Bruns DE, Goldstein DE, et al. Marian Parrott guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus Clin Chem. 2002;48:436-472.
6. Dunstan DW, Zimmet PZ, Welborn TA, et al. The rising prevalence of diabetes and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care. 2003;25:829-834.
7. Lowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science. 2005;307:384-387.
8. Winter WE. Diabetes disease management. Differentiating type 1 and type 2 diabetes. Clin Chem News. July 2005.
9. American Diabetes Association. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003;26:917-932.
10. Gerich JE. Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc. 2003;78:447-456.
11. Maechler P, Wollheim CB. Mitochondrial function in normal and diabetic β-cells. Nature. 2001;414:807-812.
12. Ohkubo K, Yamano A, Nagashima M, et al. Mitochondrial gene mutations in the tRNALeu(UUR) region and diabetes: Prevalence and clinical phenotypes in Japan. Clin Chem. 2001;47:1641-1648.
13. Bishop ML, Fody EP, Schoeff L. Clinical Chemistry, Principles, Procedures, Correlation, 5th edition. Philadelphia: Lippincott Williams and Wilkins, 2005.
14. Krishnamurti U, Steffes MW. Glycohemoglobin: A primary predictor of the development or reversal of complications of diabetes mellitus. Clin Chem. 2001;47:1157-1165.
15. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999;48:937-942.
16. Kawabata Y, Ikegami H, Kawaguchi Y, et al. Asian-specific HLA haplotypes reveal heterogeneity of the contribution of HLA-DR and -DQ haplotypes to susceptibility to Type 1 diabetes. Diabetes. 2002;51:545-551.
17. Steven CD. Clinical immunology and serology. A laboratory perspective. Philadelphia: F.A. Davis Company, 1996.
18. Turgeon ML. Immunology and Serology in Laboratory Medicine 2nd edition. St. Louis: Mosby 1996.
19. She J-X. Susceptibility to type 1 diabetes: HLA-DQ and DR revisited. Immunology Today. 1996;17:323-329.
20. Baisch JM, Weeks T, Giles R, et al. Analysis of HLA-DQ genotypes and susceptibility in insulin-dependent diabetes mellitus. New Engl J Med. 1990;322:1836-1841
21. Lernmark A. Type 1 diabetes. Clin Chem. 1999;45:1331-1338.
22. Baumann-Antczak A, Kosowicz J, Gryczynska M, et al. The prevalence of autoantibodies to pituitary carboxypeptidase E in autoimmune Addison's disease. Polish J Endocrinol. 2003;54:753-756.
23. Lebovitz HE. Type 2 diabetes: An overview. Clin Chem. 1999;45:1339-1345.
24. Spanheimer RG. Reducing cardiovascular risk in diabetes. Which factors to modify first? Postgrad Med. 2001;109:26-30,33-36.
25. Braun LT. Lipid disorders in type 2 diabetes. Nun Clin North Am. 2001;36:291-302.
26. Samuel-Hodge CD, Headen SW, Skelly AH, et al. Influence of day-to-day self-management of type 2 diabetes among African-American women. Diabetes Care. 2000;23:928-933.
27. Ogedegbe HO, Brown DW. Lipids, lipoproteins and apolipoproteins and their disease associations. Lab Med. 2001;32:384-389.
28. Ogedegbe HO. The dysmetabolic (dysmetabolic syndrome) and coronary heart disease in the African American, Hispanic and other minority populations. ABC Digest Urban Cardiol. 2002;9:17-25.
29. Gaillard TR, Schuster DP, Bossetti BM, et al. The impact of socioeconomic status on cardiovascular risk factors in African-Americans at high risk for type II diabetes. Implications for syndrome X. Diabetes Care. 1997;20:745-752.
30. Ogedegbe HO, Brown DW. Lipids, lipoproteins and apolipoproteins and their disease associations. Lab Med. 2001;32:384-389.
31. Kaplan LA, Pesce AJ. Clinical Chemistry, Theory, Analysis, Correlation. 3rd edition. St. Louis: Mosby, 1996.
32. Klupa T, Warram JH, Antonellis A, et al. Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1 a mutations. Diabetes Care. 2002;25:2292-2301.
33. Anuradha S, Radha V, Deepa R, et al. A prevalent amino acid polymorphism at codon 98 (Ala98Val) of hepatocyte nuclear factor-1-is associated with maturity-onset of type 2 diabetes in Asian Indians. Diabetes Care. 2005;28:2430-2435.
34. The Merck Manual, 17th Edition. Disorders of carbohydrate metabolism. Merck Research Laboratories, Whitehouse, 1999;165-185.
35. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26:S5-S20.
36. Turchin A, Kohane IS, Pendergrass ML. Identification of patients with diabetes from the text of physician notes in the electronic medical record. Diabetes Care. 2005;28:1794-1795.
37. Smith JJ. NCQA/HEDIS guidelines for diabetes. Managed Care. 2001;10:3-5.
38. Rohlfing CL, Little RR, Weidmeyer H-M, et al. Use of GHb (HbA1c) in screening for undiagnosed diabetes in the U.S. population. Diabetes Care. 2000;23:187-191.
39. Montori VM, Helgemoe PK, Guyatt GH, et al. Telecare for patients with type 1 diabetes and inadequate glycemic control. A randomized controlled trial and meta-analysis. Diabetes Care. 2004;27:1088-1094.
40. Weitgasser R, Gappmayer B, Pichler M. Newer portable glucose meters-analytical improvement compared with previous generation devices? Clin Chem. 1999;45:1821-1825.